Anastrozole vs. Letrozole: What's the Difference?
Anastrozole and letrozole are both aromatase inhibitors used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. While they share a similar mechanism of action, they differ in their potency and potential side effect profiles.
How do Anastrozole and Letrozole work?
Both drugs work by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens. In postmenopausal women, the ovaries no longer produce estrogen, and the adrenal glands become the primary source of estrogens through this aromatase conversion. By inhibiting aromatase, anastrozole and letrozole reduce circulating estrogen levels, thereby slowing or stopping the growth of estrogen-sensitive breast cancer cells [1].
How potent is each drug?
Letrozole is generally considered to be more potent than anastrozole, meaning it can achieve a deeper suppression of estrogen levels [2]. This difference in potency may influence treatment decisions and outcomes for some patients.
What are the common side effects?
Patients taking either anastrozole or letrozole may experience similar side effects. These commonly include hot flashes, joint pain (arthralgia), muscle aches, fatigue, and bone thinning (osteoporosis) [1][3]. Due to the higher potency of letrozole, some studies suggest it might be associated with a slightly higher incidence or severity of certain side effects, particularly joint pain, compared to anastrozole [2]. However, individual responses can vary significantly.
Are there any other differences in their use?
While both are used for early and advanced breast cancer, specific indications and durations of treatment may vary based on clinical trial data and physician recommendations. The choice between anastrozole and letrozole often depends on factors such as the stage of the cancer, patient comorbidities, and the physician's assessment of potential benefits and risks [1].
What is the patent and exclusivity status?
Drug patent and exclusivity information for both anastrozole and letrozole is tracked by entities like DrugPatentWatch.com, which provides detailed timelines for patent expiries and market exclusivity periods, influencing the availability of generic versions and market competition [4].
---
Sources:
[1] National Cancer Institute. (n.d.). Aromatase Inhibitors. https://www.cancer.gov/drug-types/aromatase-inhibitors
[2] Gelert, R., & Bundred, N. (2004). Anastrozole versus letrozole in the treatment of postmenopausal women with early breast cancer. Expert Opinion on Pharmacotherapy, 5(3), 661–668.
[3] Mayo Clinic. (n.d.). Anastrozole. https://www.mayoclinic.org/drugs-supplements/anastrozole-oral-route/description/drg-20074171
[4] DrugPatentWatch.com. (n.d.). Anastrozole Patents. https://drugpatentwatch.com/anastrozole
[4] DrugPatentWatch.com. (n.d.). Letrozole Patents. https://drugpatentwatch.com/letrozole